Parkway Life REIT (PLife REIT) FY2025 Financial Results: Robust Growth Amid Strategic Expansion
Parkway Life Real Estate Investment Trust (PLife REIT), one of Asia’s largest listed healthcare REITs, delivered a strong set of results for the second half (2H) and full year (FY) 2025. The trust demonstrated resilience and growth through strategic acquisitions, robust capital management, and a well-diversified portfolio. Below, we break down the key financial metrics, performance trends, and corporate actions that shaped FY2025.
Key Financial Metrics and Performance Table
| Metric | 2H 2025 | 2H 2024 | FY 2025 | FY 2024 | YoY Change (FY) | QoQ Change (2H) |
|---|---|---|---|---|---|---|
| Gross Revenue (S\$’000) | 77,986 | 72,848 | 156,294 | 145,268 | +7.6% | +7.1% |
| Net Property Income (S\$’000) | 73,640 | 68,242 | 147,484 | 136,597 | +8.0% | +7.9% |
| Distributable Income (S\$’000) | 49,858 | 45,810 | 99,781 | 91,419 | +9.1% | +8.8% |
| Distribution Per Unit (DPU, cents) | 7.64 | 7.38 | 15.29 | 14.92 | +2.5% | +3.5% |
| NAV per Unit (S\$) | 2.56 | 2.41 | +6.2% | |||
| Gearing | 33.4% | 33.5% | -0.1ppt | |||
Dividends
The proposed distribution per unit (DPU) for 2H 2025 is 7.64 cents, bringing the full-year DPU to 15.29 cents—up 2.5% year-on-year. This marks uninterrupted DPU growth since IPO, despite an enlarged unit base following the 2024 equity fundraising.
Historical Performance Trends
- DPU Growth: PLife REIT has grown its annual DPU by 141.9% since IPO, with no interruptions in recurring DPU growth.
- Total Return: Since IPO, the total return on invested equity stands at 391% (including appreciation of unit price and cumulative DPU).
- Unit Price: The unit price increased to S\$4.08 as at 31 December 2025, from the IPO price of S\$1.28.
Exceptional Events and Asset Revaluation
- Valuation Gain: Asset revaluation resulted in a portfolio gain of S\$135.7 million over the previous valuation and S\$64.7 million over net book value, mainly due to projected rent increases at Singapore hospitals.
- Acquisitions: The trust completed the acquisition of one nursing home in Japan (August 2024) and 11 nursing homes in France (December 2024), boosting gross revenue and NPI.
- Divestment: The Malaysia portfolio was divested in August 2025, leading to a one-off gain on disposal.
- Tax Efficiency: Obtained tax exemption on foreign-sourced income for the France portfolio, further supporting distributable income.
Corporate Actions and Fundraising
- 47,369,000 new units were issued in November 2024 via an equity fundraising to fund acquisitions and growth. This enlarged the unit base and partially diluted DPU growth for the year.
- No long-term debt refinancing needs until October 2026 due to proactive liability management and new loan facilities.
Portfolio and Strategic Highlights
- Diversification: At end-2025, the portfolio comprises 74 properties across Singapore (3 hospitals), Japan (60 nursing homes), and France (11 nursing homes) with committed occupancy rates near 100%.
- Lease Structure: Weighted average lease to expiry is 14.49 years, with 90% of revenue covered by downside-protected leases.
- Singapore Hospitals: Step-up lease agreements will drive a minimum rent increase of 24.3% in FY2026, underpinning organic rental growth.
- Defensive Positioning: The trust’s triple net lease structure and natural FX hedges for foreign assets provide stability against inflation and currency volatility.
- Strong Balance Sheet: Gearing remains healthy at 33.4%, with significant debt headroom before regulatory limits. About 93% of interest rate exposure is hedged.
Macroeconomic and Regulatory Environment
- PLife REIT’s portfolio is well-positioned within the growing healthcare sector in Asia-Pacific and Europe, benefitting from demographic trends and healthcare demand.
- There were no reported legal disputes, natural disasters, or regulatory changes impacting the trust in FY2025.
Management Commentary
Chairman’s Statement: (Not included in the report, so cannot be provided.)
Conclusion and Investment Recommendations
Overall, PLife REIT’s FY2025 performance is robust, underpinned by:
- Strong YoY growth in revenue, NPI, and distributable income
- Steady DPU growth despite equity dilution
- Resilient portfolio with quality tenants, long WALE, and high occupancy
- Visible rent escalation in Singapore hospital assets from FY2026
- Prudent capital management and ample debt headroom
Recommendation for Existing Investors
If you are currently holding PLife REIT, consider continuing to hold the stock given its defensive lease structure, visible rental growth, and solid balance sheet. The outlook remains positive with further upside from contractual rent escalations in Singapore and diversification benefits from recent European acquisitions.
Recommendation for Prospective Investors
If you do not currently hold PLife REIT, this could be a good entry opportunity for long-term, income-focused investors seeking stable distributions and exposure to healthcare real estate. However, note the unit’s premium to NAV and monitor macroeconomic risks that could affect healthcare spending or property values.
Disclaimer
This analysis is based strictly on data and disclosures from the FY2025 financial report of PLife REIT. It does not constitute investment advice. Please consult your financial advisor before making any investment decisions.
